PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22378351-7	2012	In HSC3 cells, restoration of miR-133a or silencing ARPC5 led to a reorganization of the actin cytoskeleton and a subsequent change in cell morphology to a round, bleb-like shape.	mir-133a	30-38	DnaJ heat shock protein family (Hsp40) member B7	Homo sapiens	3-7
22842467-1	2012	We tested the hypothesis that miR-133a regulates DNA methylation by inhibiting Dnmt-1 (maintenance) and Dnmt-3a and -3b (de novo) methyl transferases in diabetic hearts by using Ins2(+/-) Akita (diabetic) and C57BL/6J (WT), mice and HL1 cardiomyocytes.	mir-133a	30-38	DNA methyltransferase (cytosine-5) 1	Mus musculus	79-85
22842467-1	2012	We tested the hypothesis that miR-133a regulates DNA methylation by inhibiting Dnmt-1 (maintenance) and Dnmt-3a and -3b (de novo) methyl transferases in diabetic hearts by using Ins2(+/-) Akita (diabetic) and C57BL/6J (WT), mice and HL1 cardiomyocytes.	mir-133a	30-38	DNA methyltransferase 3A	Mus musculus	104-119
22842467-1	2012	We tested the hypothesis that miR-133a regulates DNA methylation by inhibiting Dnmt-1 (maintenance) and Dnmt-3a and -3b (de novo) methyl transferases in diabetic hearts by using Ins2(+/-) Akita (diabetic) and C57BL/6J (WT), mice and HL1 cardiomyocytes.	mir-133a	30-38	asialoglycoprotein receptor 1	Mus musculus	233-236
22842467-4	2012	The results revealed that miR-133a is inhibited but Dnmt-1 and -3b are induced in Akita suggesting that attenuation of miR-133a induces both maintenance (Dnmt-1) - and de novo - methylation (Dnmt-3b) in diabetes.	mir-133a	119-127	DNA methyltransferase (cytosine-5) 1	Mus musculus	52-66
22842467-4	2012	The results revealed that miR-133a is inhibited but Dnmt-1 and -3b are induced in Akita suggesting that attenuation of miR-133a induces both maintenance (Dnmt-1) - and de novo - methylation (Dnmt-3b) in diabetes.	mir-133a	119-127	DNA methyltransferase (cytosine-5) 1	Mus musculus	52-58
22842467-4	2012	The results revealed that miR-133a is inhibited but Dnmt-1 and -3b are induced in Akita suggesting that attenuation of miR-133a induces both maintenance (Dnmt-1) - and de novo - methylation (Dnmt-3b) in diabetes.	mir-133a	119-127	DNA methyltransferase 3B	Mus musculus	191-198
22842467-6	2012	In cardiomyocytes, over expression of miR-133a inhibits but silencing of miR-133a induces Dnmt-1, -3a and -3b elucidating the involvement of miR-133a in regulation of DNA methylation.	mir-133a	73-81	DNA methyltransferase (cytosine-5) 1	Mus musculus	90-109
22037549-6	2012	Caveolin-1 inhibiting miR-133a was reduced and caveolin-1, a negative regulator of eNOS activity, was elevated in senescent HAEC.	mir-133a	22-30	caveolin 1	Homo sapiens	0-10
22292984-11	2012	In addition, we identified a putative miR-133a binding site in the 3"-untranslated region (UTR) of Fascin1 (FSCN1) gene using an online bioinformatical tool.	mir-133a	38-46	fascin actin-bundling protein 1	Homo sapiens	99-106
22292984-11	2012	In addition, we identified a putative miR-133a binding site in the 3"-untranslated region (UTR) of Fascin1 (FSCN1) gene using an online bioinformatical tool.	mir-133a	38-46	fascin actin-bundling protein 1	Homo sapiens	108-113
22292984-12	2012	We found that miR-133a transfection significantly reduced expression of FSCN1 mRNA and protein.	mir-133a	14-22	fascin actin-bundling protein 1	Homo sapiens	72-77
22292984-15	2012	Functionally, miR-133a can suppress tumor cell invasion and migration and targeted the expression of FSCN1.	mir-133a	14-22	fascin actin-bundling protein 1	Homo sapiens	101-106
22068816-5	2012	Restoration of miR-1 or miR-133a in PC3 and DU145 cells revealed significant inhibition of proliferation, migration, and invasion.	mir-133a	24-32	chromobox 8	Homo sapiens	36-39
22089643-7	2012	Furthermore, transient transfection of miR-133a, repressed ARPC5 and GSTP1 mRNA and protein levels.	mir-133a	39-47	actin related protein 2/3 complex subunit 5	Homo sapiens	59-64
22089643-7	2012	Furthermore, transient transfection of miR-133a, repressed ARPC5 and GSTP1 mRNA and protein levels.	mir-133a	39-47	glutathione S-transferase pi 1	Homo sapiens	69-74
20520763-14	2010	The miR-133a inhibitor prevented the high glucose-induced decrease in PTB and insulin biosynthesis, and the miR-133a precursor decreased PTB levels and insulin biosynthesis similarly to high glucose.	mir-133a	4-12	polypyrimidine tract binding protein 1	Homo sapiens	70-73
21109942-4	2011	A luciferase reporter assay revealed that miR-133a is directly bound to CAV1 mRNA.	mir-133a	42-50	caveolin 1	Homo sapiens	72-76
20974915-5	2010	miR-133a inhibited Hand2 expression in tissue culture models, and miR-133a double knockout mice had elevated levels of Hand2 mRNA and protein.	mir-133a	0-8	heart and neural crest derivatives expressed 2	Mus musculus	19-24
20974915-6	2010	We conclude that Hand2 is regulated by miR-133a in addition to miR-1.	mir-133a	39-47	heart and neural crest derivatives expressed 2	Mus musculus	17-22
20520763-14	2010	The miR-133a inhibitor prevented the high glucose-induced decrease in PTB and insulin biosynthesis, and the miR-133a precursor decreased PTB levels and insulin biosynthesis similarly to high glucose.	mir-133a	4-12	insulin	Homo sapiens	78-85
20520763-14	2010	The miR-133a inhibitor prevented the high glucose-induced decrease in PTB and insulin biosynthesis, and the miR-133a precursor decreased PTB levels and insulin biosynthesis similarly to high glucose.	mir-133a	108-116	polypyrimidine tract binding protein 1	Homo sapiens	137-140
20520763-14	2010	The miR-133a inhibitor prevented the high glucose-induced decrease in PTB and insulin biosynthesis, and the miR-133a precursor decreased PTB levels and insulin biosynthesis similarly to high glucose.	mir-133a	108-116	insulin	Homo sapiens	152-159
20173049-6	2010	Mutation of these sites in the NFATc4 3"-UTR completely blocked the negative effect of miR-133a on NFATc4, suggesting that NFATc4 is a direct target for miR-133a regulation.	mir-133a	87-95	nuclear factor of activated T cells 4	Homo sapiens	99-105
20173049-0	2010	NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repression.	mir-133a	34-42	nuclear factor of activated T cells 4	Homo sapiens	0-6
20173049-6	2010	Mutation of these sites in the NFATc4 3"-UTR completely blocked the negative effect of miR-133a on NFATc4, suggesting that NFATc4 is a direct target for miR-133a regulation.	mir-133a	87-95	nuclear factor of activated T cells 4	Homo sapiens	31-37
20173049-6	2010	Mutation of these sites in the NFATc4 3"-UTR completely blocked the negative effect of miR-133a on NFATc4, suggesting that NFATc4 is a direct target for miR-133a regulation.	mir-133a	87-95	nuclear factor of activated T cells 4	Homo sapiens	99-105
20173049-8	2010	This latter effect of miR-133a on NFATc4 gene expression was coincided with an attenuated cardiomyocyte hypertrophy induced by an alpha-adrenergic receptor agonist.	mir-133a	22-30	nuclear factor of activated T cells 4	Homo sapiens	34-40
20173049-9	2010	Conversely, cells treated with miR-133a inhibitor resulted in an increase in NFATc4 expression level.	mir-133a	31-39	nuclear factor of activated T cells 4	Homo sapiens	77-83
20173049-11	2010	We conclude that the negative regulation of NFATc4 expression contributes to miR-133a-mediated hypertrophic repression.	mir-133a	77-85	nuclear factor of activated T cells 4	Homo sapiens	44-50
19015276-5	2008	These abnormalities can be attributed, at least in part, to elevated expression of SRF and cyclin D2, which are targets for repression by miR-133a.	mir-133a	138-146	serum response factor	Mus musculus	83-86
19644046-7	2009	MEASUREMENTS AND MAIN RESULTS: In hBSMCs, an up-regulation of RhoA was observed when the function of endogenous miR-133a was inhibited by its antagomir.	mir-133a	112-120	ras homolog family member A	Mus musculus	62-66
19644046-11	2009	CONCLUSIONS: These findings suggest that RhoA expression is negatively regulated by miR-133a in BSMs.	mir-133a	84-92	ras homolog family member A	Mus musculus	41-45
19073597-0	2009	In vitro evidence suggests that miR-133a-mediated regulation of uncoupling protein 2 (UCP2) is an indispensable step in myogenic differentiation.	mir-133a	32-40	uncoupling protein 2	Homo sapiens	64-84
19073597-0	2009	In vitro evidence suggests that miR-133a-mediated regulation of uncoupling protein 2 (UCP2) is an indispensable step in myogenic differentiation.	mir-133a	32-40	uncoupling protein 2	Homo sapiens	86-90
19056878-4	2008	(3242-3254) demonstrate that miR-133a functions as an inhibitor of cardiomyocyte proliferation and a modifier of serum response factor (SRF)-dependent transcriptional signaling in the murine heart.	mir-133a	29-37	serum response factor	Mus musculus	113-134
19056878-4	2008	(3242-3254) demonstrate that miR-133a functions as an inhibitor of cardiomyocyte proliferation and a modifier of serum response factor (SRF)-dependent transcriptional signaling in the murine heart.	mir-133a	29-37	serum response factor	Mus musculus	136-139
20953121-4	2010	Similarly, in human BSM cells (hBSMCs), our recent studies revealed that an upregulation of RhoA was induced when the function of endogenous miR-133a was inhibited by its antagomir.	mir-133a	141-149	ras homolog family member A	Homo sapiens	92-96
20953121-5	2010	Treatment of hBSMCs with interleukin-13 (IL-13) caused an upregulation of RhoA and a downregulation of miR-133a.	mir-133a	103-111	interleukin 13	Homo sapiens	25-39
20953121-5	2010	Treatment of hBSMCs with interleukin-13 (IL-13) caused an upregulation of RhoA and a downregulation of miR-133a.	mir-133a	103-111	interleukin 13	Homo sapiens	41-46
19015276-5	2008	These abnormalities can be attributed, at least in part, to elevated expression of SRF and cyclin D2, which are targets for repression by miR-133a.	mir-133a	138-146	cyclin D2	Mus musculus	91-100
18464261-9	2008	In tongue SCC cell lines, PKM2 expression was reduced in response to miR-133a and miR-133b precursors transfection.	mir-133a	69-77	serpin family B member 3	Homo sapiens	10-13
18464261-9	2008	In tongue SCC cell lines, PKM2 expression was reduced in response to miR-133a and miR-133b precursors transfection.	mir-133a	69-77	pyruvate kinase M1/2	Homo sapiens	26-30
34310913-15	2021	The suppression of PPP2CA, involved in adrenergic signal transduction, and Kchip2 may indirectly mediate mir-133a-3p-induced augmentation of ICa,L and attenuation of Ito.	mir-133a	105-113	protein phosphatase 2 catalytic subunit alpha	Rattus norvegicus	19-25
34310913-15	2021	The suppression of PPP2CA, involved in adrenergic signal transduction, and Kchip2 may indirectly mediate mir-133a-3p-induced augmentation of ICa,L and attenuation of Ito.	mir-133a	105-113	potassium voltage-gated channel interacting protein 2	Rattus norvegicus	75-81
34303273-7	2021	The dual-luciferase reporter gene was used to detect the interaction between miR-133a and CTGF.	mir-133a	77-85	cellular communication network factor 2	Homo sapiens	90-94
34575979-8	2021	Further investigations showed a role of TPM4 in cancer physiology, specifically, we found that miR-133a downregulation leads to TPM4 upregulation in colon carcinoma (CRC), and this correlates with a lower patient survival.	mir-133a	95-103	tropomyosin 4	Homo sapiens	40-44
34303273-12	2021	By targeting CTGF, miR-133a inhibited the expression of CTGF.	mir-133a	19-27	cellular communication network factor 2	Homo sapiens	13-17
34303273-12	2021	By targeting CTGF, miR-133a inhibited the expression of CTGF.	mir-133a	19-27	cellular communication network factor 2	Homo sapiens	56-60
34237642-6	2021	Among those, miR-133a (which can specifically target TGFB2 (Recombinant Transforming Growth Factor Beta 2) was the most significantly downregulated with a fold-change of 5.27 in BMECs cultured with cadmium.	mir-133a	13-21	transforming growth factor, beta 2	Mus musculus	53-58
34237642-6	2021	Among those, miR-133a (which can specifically target TGFB2 (Recombinant Transforming Growth Factor Beta 2) was the most significantly downregulated with a fold-change of 5.27 in BMECs cultured with cadmium.	mir-133a	13-21	transforming growth factor, beta 2	Mus musculus	72-105
34237642-12	2021	Overall, results indicated that circ08409 could relieve the inhibitory effect of miR-133a on TGFB2 expression by combining with miR-133a and subsequently modulating cell proliferation, apoptosis and inflammation.	mir-133a	81-89	transforming growth factor, beta 2	Mus musculus	93-98
34237642-12	2021	Overall, results indicated that circ08409 could relieve the inhibitory effect of miR-133a on TGFB2 expression by combining with miR-133a and subsequently modulating cell proliferation, apoptosis and inflammation.	mir-133a	128-136	transforming growth factor, beta 2	Mus musculus	93-98
34575979-8	2021	Further investigations showed a role of TPM4 in cancer physiology, specifically, we found that miR-133a downregulation leads to TPM4 upregulation in colon carcinoma (CRC), and this correlates with a lower patient survival.	mir-133a	95-103	tropomyosin 4	Homo sapiens	128-132
34575979-10	2021	In muscles, miR-133a generates a myogenic stimulus, reducing the differentiation by downregulating TPM4.	mir-133a	12-20	tropomyosin 4	Homo sapiens	99-103
34575979-12	2021	Interestingly, in CRC cell lines and in patient biopsies, miR-133a is able to regulate TPM4 activity, while TAp63 is not active.	mir-133a	58-66	tropomyosin 4	Homo sapiens	87-91
34165368-10	2021	Our study suggested that miR-133a played an important role in maintaining the viability and balance between osteoblast and adipocyte differentiation of BMSCs through the MAPK/ERK signaling pathway by targeting FGFR1.	mir-133a	25-33	mitogen-activated protein kinase 1	Mus musculus	175-178
34539887-0	2021	FOXD3-induced miR-133a blocks progression and metastasis of colorectal cancer through regulating UBA2.	mir-133a	14-22	forkhead box D3	Homo sapiens	0-5
34539887-0	2021	FOXD3-induced miR-133a blocks progression and metastasis of colorectal cancer through regulating UBA2.	mir-133a	14-22	ubiquitin like modifier activating enzyme 2	Homo sapiens	97-101
34387094-13	2021	Furin was elevated in this murine model of TAA and repressed by miR-133a replacement in vivo resulting in reduced proteolytic activation.	mir-133a	64-72	furin (paired basic amino acid cleaving enzyme)	Mus musculus	0-5
34165368-10	2021	Our study suggested that miR-133a played an important role in maintaining the viability and balance between osteoblast and adipocyte differentiation of BMSCs through the MAPK/ERK signaling pathway by targeting FGFR1.	mir-133a	25-33	fibroblast growth factor receptor 1	Mus musculus	210-215
34350837-10	2021	Furthermore, ANKRD44 upregulation eliminated the anti-osteogenic differentiation effects of miR-133a-3p in BMSCs.	mir-133a	92-100	ankyrin repeat domain 44	Mus musculus	13-20
34225723-16	2021	Tim-1 knockdown impaired the invasion, migration, proliferation of U251 and U87 cells, which could be reversed by miR-133a downregulation.	mir-133a	114-122	hepatitis A virus cellular receptor 1	Homo sapiens	0-5
34225723-17	2021	miR-133a upregulation inhibited the proliferation, invasion, and migration of U251 and U87 cells, which could be reversed by TGFBR1 upregulation.	mir-133a	0-8	transforming growth factor beta receptor 1	Homo sapiens	125-131
34225723-18	2021	Tim-1 knockdown and miR-133a upregulation could inhibit the activation of the Wnt/beta-catenin pathway, while the elevation of TGFBR1 showed opposite effects.	mir-133a	20-28	catenin beta 1	Homo sapiens	82-94
34225723-18	2021	Tim-1 knockdown and miR-133a upregulation could inhibit the activation of the Wnt/beta-catenin pathway, while the elevation of TGFBR1 showed opposite effects.	mir-133a	20-28	transforming growth factor beta receptor 1	Homo sapiens	127-133
34226535-7	2021	Immunofluorescence staining, luciferase reporter, and m6A-RIP (RNA immunoprecipitation) assays revealed that m6A modification facilitated miR-133a binding to and repressing their targets.	mir-133a	138-146	receptor interacting serine/threonine kinase 1	Homo sapiens	58-61
34080664-0	2021	(Retracted) miR-133a inhibits cervical cancer growth by targeting EGFR.	mir-133a	12-20	epidermal growth factor receptor	Homo sapiens	66-70
34226535-9	2021	IGF2BP2, an m6A binding protein, physically interacted with AGO2 and increased more miR-133a accumulation on its target site, which was modified by m6A.	mir-133a	84-92	insulin like growth factor 2 mRNA binding protein 2	Homo sapiens	0-7
34226535-9	2021	IGF2BP2, an m6A binding protein, physically interacted with AGO2 and increased more miR-133a accumulation on its target site, which was modified by m6A.	mir-133a	84-92	argonaute RISC catalytic component 2	Homo sapiens	60-64
35432524-0	2022	IL-6 Promotes Hepatocellular Carcinoma Invasion by Releasing Exosomal miR-133a-3p.	mir-133a	70-78	interleukin 6	Homo sapiens	0-4
35524907-6	2022	The most relevant pathway regulated by miR-133a was ErbB2 signaling, whose main genes involved are EGFR, ERBB2, and RHOA, which are possibly downregulated by miR133a.	mir-133a	39-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-57
35524907-6	2022	The most relevant pathway regulated by miR-133a was ErbB2 signaling, whose main genes involved are EGFR, ERBB2, and RHOA, which are possibly downregulated by miR133a.	mir-133a	39-47	epidermal growth factor receptor	Homo sapiens	99-103
35524907-6	2022	The most relevant pathway regulated by miR-133a was ErbB2 signaling, whose main genes involved are EGFR, ERBB2, and RHOA, which are possibly downregulated by miR133a.	mir-133a	39-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	105-110
35524907-6	2022	The most relevant pathway regulated by miR-133a was ErbB2 signaling, whose main genes involved are EGFR, ERBB2, and RHOA, which are possibly downregulated by miR133a.	mir-133a	39-47	ras homolog family member A	Homo sapiens	116-120
35456995-0	2022	Inhibition of RhoA and Cdc42 by miR-133a Modulates Retinoic Acid Signalling during Early Development of Posterior Cardiac Tube Segment.	mir-133a	32-40	ras homolog family member A	Gallus gallus	14-18
35456995-0	2022	Inhibition of RhoA and Cdc42 by miR-133a Modulates Retinoic Acid Signalling during Early Development of Posterior Cardiac Tube Segment.	mir-133a	32-40	cell division cycle 42	Gallus gallus	23-28
35456995-6	2022	Furthermore, we observed that miR-133a upregulates p21 and downregulates cyclin A by repressing RhoA and Cdc42, respectively, thus functioning as a cell proliferation inhibitor.	mir-133a	30-38	cyclin A2	Gallus gallus	73-81
35456995-6	2022	Furthermore, we observed that miR-133a upregulates p21 and downregulates cyclin A by repressing RhoA and Cdc42, respectively, thus functioning as a cell proliferation inhibitor.	mir-133a	30-38	ras homolog family member A	Gallus gallus	96-100
35456995-6	2022	Furthermore, we observed that miR-133a upregulates p21 and downregulates cyclin A by repressing RhoA and Cdc42, respectively, thus functioning as a cell proliferation inhibitor.	mir-133a	30-38	cell division cycle 42	Gallus gallus	105-110
35456995-8	2022	Given that RhoA and Cdc42 are involved in Raldh2 expression and that they are modulated by miR-133a, which is influenced by retinoic acid signalling, our results suggest the presence of a negative feedback mechanism between miR-133a and retinoic acid during early development of the posterior cardiac tube segment.	mir-133a	91-99	cell division cycle 42	Gallus gallus	20-25
35456995-8	2022	Given that RhoA and Cdc42 are involved in Raldh2 expression and that they are modulated by miR-133a, which is influenced by retinoic acid signalling, our results suggest the presence of a negative feedback mechanism between miR-133a and retinoic acid during early development of the posterior cardiac tube segment.	mir-133a	224-232	ras homolog family member A	Gallus gallus	11-15
35456995-8	2022	Given that RhoA and Cdc42 are involved in Raldh2 expression and that they are modulated by miR-133a, which is influenced by retinoic acid signalling, our results suggest the presence of a negative feedback mechanism between miR-133a and retinoic acid during early development of the posterior cardiac tube segment.	mir-133a	224-232	cell division cycle 42	Gallus gallus	20-25
35279129-13	2022	Notably, circFADS2 overexpression reduced the effects of miR-133a on LPS-treated HBEpCs.	mir-133a	57-65	fatty acid desaturase 2	Homo sapiens	9-18
35101688-6	2022	The interaction relationship of miR-133a-3p and PURB was identified.	mir-133a	32-40	purine rich element binding protein B	Homo sapiens	48-52
35119583-6	2022	These exosomes then delivered miR-133a into cardiomyocytes to target ELAVL1 and repressed cardiomyocyte pyroptosis.	mir-133a	30-38	ELAV like RNA binding protein 1	Homo sapiens	69-75
33453713-12	2021	It is collectively demonstrated that miR-133a-3p can relieve the oxidative stress-induced apoptosis in the trophoblast cells through the BACH1/Nrf2/HO-1 signaling pathway via targeting BACH1 directly.	mir-133a	37-45	BTB domain and CNC homolog 1	Homo sapiens	137-142
35273681-4	2022	Expression of MMP-9 and LASP1 in H441 cellstreated by miR-133a mimics was determined by western blot.	mir-133a	54-62	matrix metallopeptidase 9	Homo sapiens	14-19
35273681-4	2022	Expression of MMP-9 and LASP1 in H441 cellstreated by miR-133a mimics was determined by western blot.	mir-133a	54-62	LIM and SH3 protein 1	Homo sapiens	24-29
33453713-12	2021	It is collectively demonstrated that miR-133a-3p can relieve the oxidative stress-induced apoptosis in the trophoblast cells through the BACH1/Nrf2/HO-1 signaling pathway via targeting BACH1 directly.	mir-133a	37-45	NFE2 like bZIP transcription factor 2	Homo sapiens	143-147
33453713-12	2021	It is collectively demonstrated that miR-133a-3p can relieve the oxidative stress-induced apoptosis in the trophoblast cells through the BACH1/Nrf2/HO-1 signaling pathway via targeting BACH1 directly.	mir-133a	37-45	heme oxygenase 1	Homo sapiens	148-152
33453713-12	2021	It is collectively demonstrated that miR-133a-3p can relieve the oxidative stress-induced apoptosis in the trophoblast cells through the BACH1/Nrf2/HO-1 signaling pathway via targeting BACH1 directly.	mir-133a	37-45	BTB domain and CNC homolog 1	Homo sapiens	185-190
32758622-0	2020	Upregulation of miR-133a-3p enhances Bufothionine-induced gastric cancer cell death by modulating IGF1R/PI3K/Akt signal pathway mediated ER stress.	mir-133a	16-24	insulin-like growth factor I receptor	Mus musculus	98-103
33654410-3	2021	This study aims to study the regulatory role of KDM5C on modification of miR-133a in the progression of lung cancer.	mir-133a	73-81	lysine demethylase 5C	Homo sapiens	48-53
33654410-10	2021	Moreover, miR-133a downregulated PTBP1 expression, whereas overexpression of PTBP1 attenuated the suppressive effect of miR-133a on lung cancer cell aggressiveness.	mir-133a	10-18	polypyrimidine tract binding protein 1	Homo sapiens	33-38
33654410-10	2021	Moreover, miR-133a downregulated PTBP1 expression, whereas overexpression of PTBP1 attenuated the suppressive effect of miR-133a on lung cancer cell aggressiveness.	mir-133a	120-128	polypyrimidine tract binding protein 1	Homo sapiens	77-82
33531645-7	2022	Transfection of miR-133a mimic induced apoptosis and inhibited OSCC cell proliferation, migration, and invasion and this was demonstrated to be attributable to decreased CTBP2 expression and suppression of the Notch signaling pathway.	mir-133a	16-24	C-terminal binding protein 2	Homo sapiens	170-175
33531645-7	2022	Transfection of miR-133a mimic induced apoptosis and inhibited OSCC cell proliferation, migration, and invasion and this was demonstrated to be attributable to decreased CTBP2 expression and suppression of the Notch signaling pathway.	mir-133a	16-24	notch receptor 1	Homo sapiens	210-215
33531645-8	2022	Taken together, we concluded that miR-133a acted as a tumor suppressor in OSCC through inhibition of the Notch signaling pathway via binding to CTBP2.	mir-133a	34-42	notch receptor 1	Homo sapiens	105-110
33531645-8	2022	Taken together, we concluded that miR-133a acted as a tumor suppressor in OSCC through inhibition of the Notch signaling pathway via binding to CTBP2.	mir-133a	34-42	C-terminal binding protein 2	Homo sapiens	144-149
33131307-6	2020	We also tested the hypothesis that TNF inhibits intrarenal AGT expression by a mechanism involving miR-133a.	mir-133a	99-107	tumor necrosis factor	Mus musculus	35-38
33131307-6	2020	We also tested the hypothesis that TNF inhibits intrarenal AGT expression by a mechanism involving miR-133a.	mir-133a	99-107	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	59-62
33074595-0	2020	MiR-133a acts as a tumor suppressor in lung cancer progression by regulating the LASP1 and TGF-beta/Smad3 signaling pathway.	mir-133a	0-8	LIM and SH3 protein 1	Homo sapiens	81-86
33074595-0	2020	MiR-133a acts as a tumor suppressor in lung cancer progression by regulating the LASP1 and TGF-beta/Smad3 signaling pathway.	mir-133a	0-8	transforming growth factor alpha	Homo sapiens	91-99
33074595-0	2020	MiR-133a acts as a tumor suppressor in lung cancer progression by regulating the LASP1 and TGF-beta/Smad3 signaling pathway.	mir-133a	0-8	SMAD family member 3	Homo sapiens	100-105
33074595-12	2020	In addition, miR-133a mimic suppressed tumor growth by modulating the TGF-beta/Smad3 pathway in vivo.	mir-133a	13-21	transforming growth factor alpha	Homo sapiens	70-78
33074595-12	2020	In addition, miR-133a mimic suppressed tumor growth by modulating the TGF-beta/Smad3 pathway in vivo.	mir-133a	13-21	SMAD family member 3	Homo sapiens	79-84
33074595-13	2020	CONCLUSIONS: In conclusion, miR-133a acted as a tumor suppressor in lung cancer progression by regulating the LASP1 and TGF-beta/Smad3 signaling pathway.	mir-133a	28-36	LIM and SH3 protein 1	Homo sapiens	110-115
33074595-13	2020	CONCLUSIONS: In conclusion, miR-133a acted as a tumor suppressor in lung cancer progression by regulating the LASP1 and TGF-beta/Smad3 signaling pathway.	mir-133a	28-36	transforming growth factor alpha	Homo sapiens	120-128
33074595-13	2020	CONCLUSIONS: In conclusion, miR-133a acted as a tumor suppressor in lung cancer progression by regulating the LASP1 and TGF-beta/Smad3 signaling pathway.	mir-133a	28-36	SMAD family member 3	Homo sapiens	129-134
33059643-9	2020	SNHG14 was revealed to compete with HOXB13 for miR-133a binding in A549/DDP cells.	mir-133a	47-55	small nucleolar RNA host gene 14	Homo sapiens	0-6
33059643-9	2020	SNHG14 was revealed to compete with HOXB13 for miR-133a binding in A549/DDP cells.	mir-133a	47-55	homeobox B13	Homo sapiens	36-42
33059643-10	2020	Inhibition of miR-133a in A549 cells could reverse the promotive effects of SNHG14 knockdown on DDP-sensitivity, as well as the inhibitory effects on HOXB13 expression.	mir-133a	14-22	small nucleolar RNA host gene 14	Homo sapiens	76-82
33059643-10	2020	Inhibition of miR-133a in A549 cells could reverse the promotive effects of SNHG14 knockdown on DDP-sensitivity, as well as the inhibitory effects on HOXB13 expression.	mir-133a	14-22	homeobox B13	Homo sapiens	150-156
33059643-11	2020	HOXB13 overexpression was revealed to abolish the enhanced effects of miR-133a on the sensitivity of A549/DDP cell to DDP.	mir-133a	70-78	homeobox B13	Homo sapiens	0-6
31144791-0	2020	MiR-133a suppressed cell migration and invasion by targeting SOX4 in non-small cell lung cancer.	mir-133a	0-8	SRY-box transcription factor 4	Homo sapiens	61-65
32771944-8	2020	Further, dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay were carried out to confirm the relationship between miR-133a and sirtuin-1 (SIRT1).	mir-133a	133-141	sirtuin 1	Mus musculus	146-155
32771944-8	2020	Further, dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay were carried out to confirm the relationship between miR-133a and sirtuin-1 (SIRT1).	mir-133a	133-141	sirtuin 1	Mus musculus	157-162
32771944-14	2020	CONCLUSION: MiR-133a promoted the inflammatory response of sepsis by inhibiting the expression of SIRT1, which might provide a new therapeutic strategy for sepsis.	mir-133a	12-20	sirtuin 1	Mus musculus	98-103
32758622-0	2020	Upregulation of miR-133a-3p enhances Bufothionine-induced gastric cancer cell death by modulating IGF1R/PI3K/Akt signal pathway mediated ER stress.	mir-133a	16-24	thymoma viral proto-oncogene 1	Mus musculus	109-112
32902711-2	2020	Hence, the aim of the present study was to investigate the regulatory role of miR-133a-3p on the regulation of vascular endothelial injury-induced IA through phosphoserine aminotransferase 1 (PSAT1)/glycogen synthase kinase 3beta (GSK3beta)/beta-catenin signaling pathway.	mir-133a	78-86	phosphoserine aminotransferase 1	Homo sapiens	158-190
32902711-2	2020	Hence, the aim of the present study was to investigate the regulatory role of miR-133a-3p on the regulation of vascular endothelial injury-induced IA through phosphoserine aminotransferase 1 (PSAT1)/glycogen synthase kinase 3beta (GSK3beta)/beta-catenin signaling pathway.	mir-133a	78-86	glycogen synthase kinase 3 beta	Homo sapiens	199-229
32902711-2	2020	Hence, the aim of the present study was to investigate the regulatory role of miR-133a-3p on the regulation of vascular endothelial injury-induced IA through phosphoserine aminotransferase 1 (PSAT1)/glycogen synthase kinase 3beta (GSK3beta)/beta-catenin signaling pathway.	mir-133a	78-86	phosphoserine aminotransferase 1	Homo sapiens	192-197
32196613-0	2020	MiR-133a alleviates renal injury caused by sepsis by targeting BNIP3L.	mir-133a	0-8	BCL2/adenovirus E1B interacting protein 3-like	Mus musculus	63-69
32902711-2	2020	Hence, the aim of the present study was to investigate the regulatory role of miR-133a-3p on the regulation of vascular endothelial injury-induced IA through phosphoserine aminotransferase 1 (PSAT1)/glycogen synthase kinase 3beta (GSK3beta)/beta-catenin signaling pathway.	mir-133a	78-86	glycogen synthase kinase 3 alpha	Homo sapiens	231-239
32902711-2	2020	Hence, the aim of the present study was to investigate the regulatory role of miR-133a-3p on the regulation of vascular endothelial injury-induced IA through phosphoserine aminotransferase 1 (PSAT1)/glycogen synthase kinase 3beta (GSK3beta)/beta-catenin signaling pathway.	mir-133a	78-86	catenin beta 1	Homo sapiens	241-253
33222435-0	2020	MiR-133a Promoted cerebral ischemia/reperfusion injury by targeting brain-derived neurotrophic factor.	mir-133a	0-8	brain derived neurotrophic factor	Homo sapiens	68-101
31926162-0	2020	Knockdown of TUG 1 suppresses hypoxia-induced apoptosis of cardiomyocytes by up-regulating miR-133a.	mir-133a	91-99	taurine up-regulated 1	Homo sapiens	13-18
31926162-11	2020	Mechanistically, miR-133a overturned TUG 1 overexpression-mediated inhibition of proliferation and promotion on apoptosis in AC16 cells under hypoxic condition.	mir-133a	17-25	taurine up-regulated 1	Homo sapiens	37-42
32196613-13	2020	CONCLUSIONS: The miR-133a expression was decreased in TCMK-1 cells treated by LPS and miR-133a can inhibit inflammation and apoptosis of TCMK-1 cells induced by LPS by targeting BNIP3L via inhibiting NF-kappaB pathway.	mir-133a	17-25	BCL2/adenovirus E1B interacting protein 3-like	Mus musculus	178-184
31207081-6	2019	Moreover, miR-133a inhibition significantly reversed the suppression effects of DLEU1 knockdown on HCC cells.	mir-133a	10-18	deleted in lymphocytic leukemia 1	Homo sapiens	80-85
32104215-9	2020	Overexpression of miR-133a inhibited glioma proliferation, metastasis and EMT via reducing the expression of SOX4; in contrast, knockdown of miR-133a exhibited the opposite effect, which revealed that miR-133a negatively regulates glioma progression.	mir-133a	18-26	SRY-box transcription factor 4	Homo sapiens	109-113
33132251-4	2020	In human BSM cells (hBSMCs), an up-regulation of RhoA was observed when the function of endogenous miR-133a was inhibited by its antagomir.	mir-133a	99-107	ras homolog family member A	Homo sapiens	49-53
31381269-5	2019	MiR-133a and CTGF expression in U87, A172, and HEB cell lines was determined.	mir-133a	0-8	transcription factor 12	Homo sapiens	47-50
30932200-7	2019	Subsequently, we validated that miR-133a functioned as a potential target of NEAT1.	mir-133a	32-40	nuclear paraspeckle assembly transcript 1	Homo sapiens	77-82
31152485-13	2019	Treatment with miR-133a/b mimics diminished ZFHX3 KD-induced atrial ectopy in mice.	mir-133a	15-23	zinc finger homeobox 3	Mus musculus	44-49
31511493-4	2019	Our data show that miR-133a was significantly upregulated by TGF-beta1 in a time- and concentration-dependent manner.	mir-133a	19-27	transforming growth factor beta 1	Homo sapiens	61-70
31511493-5	2019	Surprisingly, miR-133a inhibits TGF-beta1-induced myofibroblast differentiation whereas miR-133a inhibitor enhances TGF-beta1-induced myofibroblast differentiation.	mir-133a	14-22	transforming growth factor beta 1	Homo sapiens	32-41
31511493-5	2019	Surprisingly, miR-133a inhibits TGF-beta1-induced myofibroblast differentiation whereas miR-133a inhibitor enhances TGF-beta1-induced myofibroblast differentiation.	mir-133a	88-96	transforming growth factor beta 1	Homo sapiens	116-125
31511493-6	2019	Interestingly, quantitative proteomics analysis indicates that miR-133a attenuates myofibroblast differentiation via targeting multiple components of TGF-beta1 profibrogenic pathways.	mir-133a	63-71	transforming growth factor beta 1	Homo sapiens	150-159
31511493-7	2019	Western blot analysis confirmed that miR-133a down-regulates TGF-beta1-induced expression of classic myofibroblast differentiation markers such as alpha-smooth muscle actin (alpha-SMA), connective tissue growth factor (CTGF) and collagens.	mir-133a	37-45	transforming growth factor beta 1	Homo sapiens	61-70
31511493-10	2019	Together, our study identified TGF-beta1-induced miR-133a as an anti-fibrotic factor.	mir-133a	49-57	transforming growth factor beta 1	Homo sapiens	31-40
31452742-5	2019	miR-133a targets and downregulates the expression of matrix metalloproteinase (MMP)14; however, MMP15, MMP16 and MMP24 were determined to be unaffected.	mir-133a	0-8	matrix metallopeptidase 14	Homo sapiens	53-85
30610843-12	2019	In addition, brazilein inhibited the activations of MAPK and JNK pathways by up-regulating miR-133a expression.	mir-133a	91-99	mitogen-activated protein kinase 8	Homo sapiens	61-64
29957467-8	2018	Mechanistically, miR-133a was identified to serve as a direct downstream target of PVT1 in OC.	mir-133a	17-25	Pvt1 oncogene	Homo sapiens	83-87
30462772-12	2018	Knockdown of miR-133a reversed the APS treatment-induced inactivation of JNK pathway in MG63 cells.	mir-133a	13-21	mitogen-activated protein kinase 8	Homo sapiens	73-76
30086463-0	2018	MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF-beta/Smad3 signaling pathway.	mir-133a	0-8	FOS like 2, AP-1 transcription factor subunit	Homo sapiens	76-81
30086463-0	2018	MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF-beta/Smad3 signaling pathway.	mir-133a	0-8	transforming growth factor beta 1	Homo sapiens	90-98
30086463-0	2018	MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF-beta/Smad3 signaling pathway.	mir-133a	0-8	SMAD family member 3	Homo sapiens	99-104
30086463-7	2018	Furthermore, we verified that overexpression of miR-133a suppressed biological behaviour of HCC through TGF-beta/Smad3 signaling pathway.	mir-133a	48-56	transforming growth factor beta 1	Homo sapiens	104-112
30086463-7	2018	Furthermore, we verified that overexpression of miR-133a suppressed biological behaviour of HCC through TGF-beta/Smad3 signaling pathway.	mir-133a	48-56	SMAD family member 3	Homo sapiens	113-118
30161272-6	2019	Dual-luciferase reporter assay was conducted to verify whether PSEN1 was a direct target of miR-133a.	mir-133a	92-100	presenilin 1	Homo sapiens	63-68
30161272-9	2019	miR-133a suppression accelerated transforming growth factor-beta1 (TGF-beta1)-induce EMT, as evidenced by upregulation of E-cadherin, and downregulation of N-cadherin, vimentin, and Slug.	mir-133a	0-8	transforming growth factor beta 1	Homo sapiens	33-65
30161272-9	2019	miR-133a suppression accelerated transforming growth factor-beta1 (TGF-beta1)-induce EMT, as evidenced by upregulation of E-cadherin, and downregulation of N-cadherin, vimentin, and Slug.	mir-133a	0-8	transforming growth factor beta 1	Homo sapiens	67-76
30161272-9	2019	miR-133a suppression accelerated transforming growth factor-beta1 (TGF-beta1)-induce EMT, as evidenced by upregulation of E-cadherin, and downregulation of N-cadherin, vimentin, and Slug.	mir-133a	0-8	cadherin 1	Homo sapiens	122-132
30161272-9	2019	miR-133a suppression accelerated transforming growth factor-beta1 (TGF-beta1)-induce EMT, as evidenced by upregulation of E-cadherin, and downregulation of N-cadherin, vimentin, and Slug.	mir-133a	0-8	cadherin 2	Homo sapiens	156-166
30161272-9	2019	miR-133a suppression accelerated transforming growth factor-beta1 (TGF-beta1)-induce EMT, as evidenced by upregulation of E-cadherin, and downregulation of N-cadherin, vimentin, and Slug.	mir-133a	0-8	vimentin	Homo sapiens	168-176
30161272-9	2019	miR-133a suppression accelerated transforming growth factor-beta1 (TGF-beta1)-induce EMT, as evidenced by upregulation of E-cadherin, and downregulation of N-cadherin, vimentin, and Slug.	mir-133a	0-8	snail family transcriptional repressor 2	Homo sapiens	182-186
30161272-10	2019	Of contrast, miR-133a overexpression blocked TGF-beta1-induce EMT by altering these factors.	mir-133a	13-21	transforming growth factor beta 1	Homo sapiens	45-54
30161272-11	2019	PSEN1 was a direct target of miR-133a, and suppression of PSEN1 abolished the promoting functions of miR-133 suppression on cell growth and metastasis.	mir-133a	29-37	presenilin 1	Homo sapiens	0-5
30161272-14	2019	Additionally, miR-133a acts as a tumor suppressor may be via targeting PSEN1.	mir-133a	14-22	presenilin 1	Homo sapiens	71-76
29771401-0	2018	MiR-133a inhibits fracture healing via targeting RUNX2/BMP2.	mir-133a	0-8	RUNX family transcription factor 2	Homo sapiens	49-54
30185650-0	2018	Hypercapnia increases airway smooth muscle contractility via caspase-7-mediated miR-133a-RhoA signaling.	mir-133a	80-88	caspase 7	Homo sapiens	61-70
30185650-0	2018	Hypercapnia increases airway smooth muscle contractility via caspase-7-mediated miR-133a-RhoA signaling.	mir-133a	80-88	ras homolog family member A	Homo sapiens	89-93
30185650-7	2018	Deletion of the Caspase-7 gene prevented hypercapnia-induced airway contractility, which was restored by lentiviral transfection of a miR-133a antagonist.	mir-133a	134-142	caspase 7	Homo sapiens	16-25
29805563-10	2018	USP39 was a firsthand target of miR-133a and there was a negative correlation between them.	mir-133a	32-40	ubiquitin specific peptidase 39	Homo sapiens	0-5
29789398-9	2018	Moreover, miR-133a antagonism-induced angiogenesis was abolished by GCH1 inhibitor.	mir-133a	10-18	GTP cyclohydrolase 1	Mus musculus	68-72
29771401-0	2018	MiR-133a inhibits fracture healing via targeting RUNX2/BMP2.	mir-133a	0-8	bone morphogenetic protein 2	Homo sapiens	55-59
29771401-1	2018	OBJECTIVE: To analyze the mechanism of miR-133a in inhibiting fracture healing through regulating runt-related transcription factor 2 (RUNX2) signaling pathway.	mir-133a	39-47	RUNX family transcription factor 2	Homo sapiens	98-133
29771401-1	2018	OBJECTIVE: To analyze the mechanism of miR-133a in inhibiting fracture healing through regulating runt-related transcription factor 2 (RUNX2) signaling pathway.	mir-133a	39-47	RUNX family transcription factor 2	Homo sapiens	135-140
29771401-7	2018	Pearson correlation analysis showed that miR-133a was negatively correlated with RUNX2.	mir-133a	41-49	RUNX family transcription factor 2	Homo sapiens	81-86
29771401-8	2018	After overexpression of miR-133a, the expression level of RUNX2 was decreased, but it was increased significantly after interference in miR-133a.	mir-133a	24-32	RUNX family transcription factor 2	Homo sapiens	58-63
29771401-9	2018	Besides, it was found in dual-luciferase reporter assay that miR-133a bound to RUNX2.	mir-133a	61-69	RUNX family transcription factor 2	Homo sapiens	79-84
29771401-10	2018	CONCLUSIONS: MiR-133a inhibits the bone formation through inhibiting the RUNX2/BMP2 signaling pathway, thereby negatively regulating the fracture healing.	mir-133a	13-21	RUNX family transcription factor 2	Homo sapiens	73-78
29771401-10	2018	CONCLUSIONS: MiR-133a inhibits the bone formation through inhibiting the RUNX2/BMP2 signaling pathway, thereby negatively regulating the fracture healing.	mir-133a	13-21	bone morphogenetic protein 2	Homo sapiens	79-83
29506853-7	2018	miR-133a and miR-208a were significantly related to IL-6 (r = 0.287, P = 0.036; r = 0.292, P = 0.032, respectively).	mir-133a	0-8	interleukin 6	Homo sapiens	52-56
29268138-14	2018	TUG1 could function as a molecular sponge of miR-133a to suppress its expression.	mir-133a	45-53	taurine upregulated gene 1	Mus musculus	0-4
29207145-9	2018	Furthermore, overexpression of LASP1 impaired the suppressive effects of miR-133a upregulation on the proliferation, migration and invasion of SK-BR-3 and MDA-MB-231 cells.	mir-133a	73-81	LIM and SH3 protein 1	Homo sapiens	31-36
29207145-10	2018	In summary, the present study demonstrates that miR-133a acts as a tumor suppressor in breast cancer partly at least via targeting LASP1, and thus suggests that the miR-133a/LASP1 axis may become a potential therapeutic target for breast cancer.	mir-133a	48-56	LIM and SH3 protein 1	Homo sapiens	131-136
29207145-10	2018	In summary, the present study demonstrates that miR-133a acts as a tumor suppressor in breast cancer partly at least via targeting LASP1, and thus suggests that the miR-133a/LASP1 axis may become a potential therapeutic target for breast cancer.	mir-133a	48-56	LIM and SH3 protein 1	Homo sapiens	174-179
29358658-7	2018	There was a strong association between plasma miR-133a and miR-499 concentrations and postoperative troponin I concentrations, the marker for myocardial damage.	mir-133a	46-54	microRNA 499a	Homo sapiens	59-66
29268138-16	2018	Moreover, fibroblast growth factor 1 (FGF1) was identified as a direct target of miR-133a.	mir-133a	81-89	fibroblast growth factor 1	Mus musculus	10-36
29268138-16	2018	Moreover, fibroblast growth factor 1 (FGF1) was identified as a direct target of miR-133a.	mir-133a	81-89	fibroblast growth factor 1	Mus musculus	38-42
30300116-11	2018	Further investigations revealed that miR-133a reversed the biological effects of AFAP1-AS1 on PC cells.	mir-133a	37-45	actin filament associated protein 1	Homo sapiens	81-86
29268138-17	2018	Restored expression of FGF1 overturned the effect of miR-133a on cell proliferation, inflammatory factor secretion and apoptosis in ox-LDL-treated RAW264.7 and MOVAS cells.	mir-133a	53-61	fibroblast growth factor 1	Mus musculus	23-27
29268138-19	2018	CONCLUSION: TUG1 knockdown ameliorates atherosclerosis by modulating FGF1 via miR-133a, raising the possibility of targeting TUG1 as an atheroprotective therapeutic strategy.	mir-133a	78-86	taurine upregulated gene 1	Mus musculus	12-16
27933650-7	2017	Compared with the blank and NC groups, the miR-133a mimic and si-EGFR groups exhibited increased cell apoptosis rate but decreased EGFR, p-MEK1/2, and p-ERK1/2 protein expressions; while opposite trend was observed in the miR-133a inhibitors group.	mir-133a	43-51	epidermal growth factor receptor	Homo sapiens	65-69
30300116-11	2018	Further investigations revealed that miR-133a reversed the biological effects of AFAP1-AS1 on PC cells.	mir-133a	37-45	prostaglandin D2 receptor	Homo sapiens	87-90
28918048-0	2017	miR-133a Promotes TRAIL Resistance in Glioblastoma via Suppressing Death Receptor 5 and Activating NF-kappaB Signaling.	mir-133a	0-8	TNF superfamily member 10	Homo sapiens	18-23
28918048-0	2017	miR-133a Promotes TRAIL Resistance in Glioblastoma via Suppressing Death Receptor 5 and Activating NF-kappaB Signaling.	mir-133a	0-8	TNF receptor superfamily member 10b	Homo sapiens	67-83
28918048-3	2017	In this study, a negative correlation between DR5 expression and TRAIL resistance was observed, and miR-133a was predicted to be the most promising candidate to suppress DR5 expression.	mir-133a	100-108	TNF superfamily member 10	Homo sapiens	65-70
28918048-3	2017	In this study, a negative correlation between DR5 expression and TRAIL resistance was observed, and miR-133a was predicted to be the most promising candidate to suppress DR5 expression.	mir-133a	100-108	TNF receptor superfamily member 10b	Homo sapiens	170-173
28918048-4	2017	Further investigation demonstrated that miR-133a knockdown dramatically suppressed TRAIL resistance in glioblastoma in vitro and in vivo.	mir-133a	40-48	TNF superfamily member 10	Homo sapiens	83-88
28918048-5	2017	An NF-kappaB family member, phosphorylated IkappaBalpha (P-IkappaBalpha), was shown to be stimulated by miR-133a, leading to the activation of this signaling.	mir-133a	104-112	NFKB inhibitor alpha	Homo sapiens	43-55
28918048-5	2017	An NF-kappaB family member, phosphorylated IkappaBalpha (P-IkappaBalpha), was shown to be stimulated by miR-133a, leading to the activation of this signaling.	mir-133a	104-112	NFKB inhibitor alpha	Homo sapiens	59-71
28918048-7	2017	In conclusion, our data demonstrate that miR-133a promotes TRAIL resistance in glioblastoma by suppressing DR5 expression and activating NF-kappaB signaling.	mir-133a	41-49	TNF superfamily member 10	Homo sapiens	59-64
28918048-7	2017	In conclusion, our data demonstrate that miR-133a promotes TRAIL resistance in glioblastoma by suppressing DR5 expression and activating NF-kappaB signaling.	mir-133a	41-49	TNF receptor superfamily member 10b	Homo sapiens	107-110
28569392-4	2018	Dual luciferase reporter gene assay and Western blot were applied to verify the binding relationship between miR-133a-3p and COL1A1.	mir-133a	109-117	collagen type I alpha 1 chain	Homo sapiens	125-131
28768728-10	2017	injected with miR-133a or miR-146a had marked peritoneal neutrophil and monocyte migration, which was significantly attenuated in TLR7-/- mice.	mir-133a	14-22	toll-like receptor 7	Mus musculus	130-134
27933650-7	2017	Compared with the blank and NC groups, the miR-133a mimic and si-EGFR groups exhibited increased cell apoptosis rate but decreased EGFR, p-MEK1/2, and p-ERK1/2 protein expressions; while opposite trend was observed in the miR-133a inhibitors group.	mir-133a	43-51	epidermal growth factor receptor	Homo sapiens	131-135
27933650-8	2017	Compared with the miR-133a inhibitors group, the miR-133a inhibitors + si-EGFR group presented reduced cell survival rate, EGFR, p-MEK1/2, and p-ERK1/2 protein expressions but increased cell apoptosis rate.	mir-133a	49-57	epidermal growth factor receptor	Homo sapiens	74-78
27933650-8	2017	Compared with the miR-133a inhibitors group, the miR-133a inhibitors + si-EGFR group presented reduced cell survival rate, EGFR, p-MEK1/2, and p-ERK1/2 protein expressions but increased cell apoptosis rate.	mir-133a	49-57	epidermal growth factor receptor	Homo sapiens	123-127
27933650-9	2017	These results indicated that miR-133a could inhibit the MEK/ERK pathway to promote cell apoptosis and enhance radio-sensitivity by targeting EGFR in EC.	mir-133a	29-37	mitogen-activated protein kinase kinase 7	Homo sapiens	56-59
27933650-9	2017	These results indicated that miR-133a could inhibit the MEK/ERK pathway to promote cell apoptosis and enhance radio-sensitivity by targeting EGFR in EC.	mir-133a	29-37	mitogen-activated protein kinase 1	Homo sapiens	60-63
27933650-9	2017	These results indicated that miR-133a could inhibit the MEK/ERK pathway to promote cell apoptosis and enhance radio-sensitivity by targeting EGFR in EC.	mir-133a	29-37	epidermal growth factor receptor	Homo sapiens	141-145
27297802-3	2016	This study describes how the functionalisation of porous collagen-nanohydroxyapatite (nHA) scaffolds with miR-133a inhibiting complexes, delivered using non-viral nHA particles, enhanced human mesenchymal stem cell-mediated osteogenesis through the novel focus on a key activator of osteogenesis, Runx2.	mir-133a	106-114	RUNX family transcription factor 2	Homo sapiens	297-302
28702027-0	2017	Decreased Human Leukocyte Antigen-G Expression by miR-133a Contributes to Impairment of Proinvasion and Proangiogenesis Functions of Decidual NK Cells.	mir-133a	50-58	deoxyribonucleoside kinase	Drosophila melanogaster	142-144
27458709-9	2017	Moreover, miR-133a acted as an inhibitor in downregulating cyclinD2 in endometrial epithelial cells.	mir-133a	10-18	cyclin D2	Mus musculus	59-67
27425441-0	2016	MiR-133a regarded as a potential biomarker for benzene toxicity through targeting Caspase-9 to inhibit apoptosis induced by benzene metabolite (1,4-Benzoquinone).	mir-133a	0-8	caspase 9	Homo sapiens	82-91
27425441-5	2016	Pearson correlation analysis showed that miR-133a was reversely correlated with pro-apoptotic gene Caspase-9 in population-based study.	mir-133a	41-49	caspase 9	Homo sapiens	99-108
27282282-5	2016	The levels of miR-133a were negatively correlated with the status of N classification (N0-N1 vs. N2-N3, P=0.000), clinical stage (I-II vs. III-IV, P=0.010) and MMP-14 expression (High vs. Low, P=0.012).	mir-133a	14-22	matrix metallopeptidase 14	Homo sapiens	160-166
28109082-7	2017	To confirm that ERBB2 is a direct target of miR-133a, a luciferase reporter assay was performed.	mir-133a	44-52	erb-b2 receptor tyrosine kinase 2	Homo sapiens	16-21
28109082-9	2017	ERBB2 was a direct target of miR-133a, and it was negatively regulated by miR-133a.	mir-133a	29-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-5
28109082-10	2017	Interestingly, ERBB2 silencing has a similar impact to miR-133a overexpression, in that it significantly induced apoptosis and inhibited ERK and AKT activation.	mir-133a	55-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-20
28109082-10	2017	Interestingly, ERBB2 silencing has a similar impact to miR-133a overexpression, in that it significantly induced apoptosis and inhibited ERK and AKT activation.	mir-133a	55-63	mitogen-activated protein kinase 1	Homo sapiens	137-140
28109082-10	2017	Interestingly, ERBB2 silencing has a similar impact to miR-133a overexpression, in that it significantly induced apoptosis and inhibited ERK and AKT activation.	mir-133a	55-63	AKT serine/threonine kinase 1	Homo sapiens	145-148
28109082-11	2017	Our study showed that miR-133a inhibits the proliferation of gastric cancer cells by downregulating the expression of ERBB2 and its downstream signaling molecules p-ERK1/2 and p-AKT.	mir-133a	22-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-123
28109082-11	2017	Our study showed that miR-133a inhibits the proliferation of gastric cancer cells by downregulating the expression of ERBB2 and its downstream signaling molecules p-ERK1/2 and p-AKT.	mir-133a	22-30	mitogen-activated protein kinase 3	Homo sapiens	165-171
28109082-11	2017	Our study showed that miR-133a inhibits the proliferation of gastric cancer cells by downregulating the expression of ERBB2 and its downstream signaling molecules p-ERK1/2 and p-AKT.	mir-133a	22-30	AKT serine/threonine kinase 1	Homo sapiens	178-181
28466778-0	2017	miR-133a acts as a tumor suppressor in colorectal cancer by targeting eIF4A1.	mir-133a	0-8	eukaryotic translation initiation factor 4A1	Mus musculus	70-76
28466778-6	2017	However, the effect of miR-133a was abolished by the overexpression of eIF4A1.	mir-133a	23-31	eukaryotic translation initiation factor 4A1	Mus musculus	71-77
28466778-9	2017	Our results demonstrate that miR-133a plays a pivotal role in colorectal cancer by inhibiting cell proliferation, invasion, and migration by targeting oncogenic eukaryotic translation initiation factor 4A1, which acts as a tumor suppressor and may provide a new potential therapeutic target in colorectal cancer.	mir-133a	29-37	eukaryotic translation initiation factor 4A1	Mus musculus	161-205
28286270-7	2017	Moreover, USP39 was a direct target of miR-133a, a microRNA that has been reported to be involved in progression of PC.	mir-133a	39-47	ubiquitin specific peptidase 39	Homo sapiens	10-15
27794430-10	2016	In RAW264.7 cells, miR-133a was observed to target RBP-J and regulate its expression.	mir-133a	19-27	recombination signal binding protein for immunoglobulin kappa J region	Mus musculus	51-56
27794430-11	2016	MiR-133a mimic inhibited the maturation of DCs in cells exposed to LPS, the effect of which was reversed by overexpression of RBP-J.	mir-133a	0-8	recombination signal binding protein for immunoglobulin kappa J region	Mus musculus	126-131
27292200-9	2016	Also, increased expression of miR-133a was associated with less fibrosis and myocyte necrosis on EMB, and LV functional recovery during a mean follow-up of 3.1 years.	mir-133a	30-38	embigin	Homo sapiens	97-100
27730543-14	2016	miR-133a targeting CD47 could be a new direction in the diagnosis and treatment of laryngeal carcinoma.	mir-133a	0-8	CD47 molecule	Homo sapiens	19-23
27154818-0	2016	miR-150-5p and miR-133a suppress glioma cell proliferation and migration through targeting membrane-type-1 matrix metalloproteinase.	mir-133a	15-23	matrix metallopeptidase 14	Homo sapiens	91-131
27154818-7	2016	Transfection of miR-150-5p or miR-133a mimics into glioma cell lines reduced MT1-MMP expression and MMP-2 activation by these cells, and cell proliferation and invasion/migration were also suppressed by it.	mir-133a	30-38	matrix metallopeptidase 14	Homo sapiens	77-84
27154818-7	2016	Transfection of miR-150-5p or miR-133a mimics into glioma cell lines reduced MT1-MMP expression and MMP-2 activation by these cells, and cell proliferation and invasion/migration were also suppressed by it.	mir-133a	30-38	matrix metallopeptidase 2	Homo sapiens	100-105
27109382-7	2016	Using ox-LDL-treatment RAW 264.7 macrophages transfected with miR-133a mimics or inhibitors, we have showed that miR-133a can directly regulate the expression of TR4 in RAW 264.7 cells, thereby attenuates CD36-medide lipid accumulation.	mir-133a	62-70	nuclear receptor subfamily 2, group C, member 2	Mus musculus	162-165
27109382-7	2016	Using ox-LDL-treatment RAW 264.7 macrophages transfected with miR-133a mimics or inhibitors, we have showed that miR-133a can directly regulate the expression of TR4 in RAW 264.7 cells, thereby attenuates CD36-medide lipid accumulation.	mir-133a	113-121	nuclear receptor subfamily 2, group C, member 2	Mus musculus	162-165
27109382-9	2016	Thus, our findings suggest that miR-133a may regulate lipid accumulation in ox-LDL-stimulated RAW 264.7 macrophages via TR4-CD36 pathway.	mir-133a	32-40	nuclear receptor subfamily 2, group C, member 2	Mus musculus	120-123
26656045-0	2016	Dysregulated miR-133a Mediates Loss of Type II Collagen by Directly Targeting Matrix Metalloproteinase 9 (MMP9) in Human Intervertebral Disc Degeneration.	mir-133a	13-21	matrix metallopeptidase 9	Homo sapiens	78-104
27121102-0	2016	miR-133a enhances the sensitivity of Hep-2 cells and vincristine-resistant Hep-2v cells to cisplatin by downregulating ATP7B expression.	mir-133a	0-8	ATPase copper transporting beta	Homo sapiens	119-124
27121102-7	2016	Following treatment with 50 microM cisplatin, in Hep-2v cells expressing exogenous miR-133a we noted reduced ATP7B expression, and these cells had a significantly lower survival rate compared with the control.	mir-133a	83-91	ATPase copper transporting beta	Homo sapiens	109-114
27121102-8	2016	The present study demonstrates that miR-133a enhances the sensitivity of multidrug-resistant Hep-2v cells to cisplatin by downregulating ATP7B expression.	mir-133a	36-44	ATPase copper transporting beta	Homo sapiens	137-142
26656045-0	2016	Dysregulated miR-133a Mediates Loss of Type II Collagen by Directly Targeting Matrix Metalloproteinase 9 (MMP9) in Human Intervertebral Disc Degeneration.	mir-133a	13-21	matrix metallopeptidase 9	Homo sapiens	106-110
26656045-11	2016	MMP9 was identified as a target of miR-133a.	mir-133a	35-43	matrix metallopeptidase 9	Homo sapiens	0-4
26936647-6	2016	In addition, the results indicated that miR-133a was likely to directly target matrix metallopeptidase 9 in glioma.	mir-133a	40-48	matrix metallopeptidase 9	Homo sapiens	79-104
26134491-0	2015	miR-133a inhibits cervical cancer growth by targeting EGFR.	mir-133a	0-8	epidermal growth factor receptor	Homo sapiens	54-58
26845446-6	2016	Then, luciferase reporter assay validated IGF-1R as a downstream and functional target of miR-133a, and functional studies revealed that the anti-tumor effect of miR-133a was probably due to targeting and repressing of IGF-1R expression.	mir-133a	90-98	insulin like growth factor 1 receptor	Homo sapiens	42-48
26845446-6	2016	Then, luciferase reporter assay validated IGF-1R as a downstream and functional target of miR-133a, and functional studies revealed that the anti-tumor effect of miR-133a was probably due to targeting and repressing of IGF-1R expression.	mir-133a	162-170	insulin like growth factor 1 receptor	Homo sapiens	42-48
26845446-6	2016	Then, luciferase reporter assay validated IGF-1R as a downstream and functional target of miR-133a, and functional studies revealed that the anti-tumor effect of miR-133a was probably due to targeting and repressing of IGF-1R expression.	mir-133a	162-170	insulin like growth factor 1 receptor	Homo sapiens	219-225
26845446-8	2016	Furthermore, the tumour-suppressive function of miR-133a probably contributed to inhibiting the activation AKT and ERK signaling pathway.	mir-133a	48-56	AKT serine/threonine kinase 1	Homo sapiens	107-110
26845446-9	2016	CONCLUSION: MiR-133a suppresses osteosarcoma progression and metastasis by targeting IGF-1R in human osteosarcoma cells, providing a novel candidate prognostic factor and a potential anti-metastasis therapeutic target in osteosarcoma.	mir-133a	12-20	insulin like growth factor 1 receptor	Homo sapiens	85-91
26156803-8	2015	Furthermore, overexpression of miR-133a inhibited activation AKT and ERK signal pathway, which contributed to suppression of HCC cell growth.	mir-133a	31-39	AKT serine/threonine kinase 1	Homo sapiens	61-64
26156803-8	2015	Furthermore, overexpression of miR-133a inhibited activation AKT and ERK signal pathway, which contributed to suppression of HCC cell growth.	mir-133a	31-39	mitogen-activated protein kinase 1	Homo sapiens	69-72
26156803-9	2015	These findings suggest that miR-133a may act as a tumor suppressor and inhibited survival of HCC cells by targeting IGF-1R.	mir-133a	28-36	insulin like growth factor 1 receptor	Homo sapiens	116-122
26173501-8	2015	Moreover, upregulation of FSCN1 and downregulation of miR-145 and miR-133a co-existed in HCC.	mir-133a	66-74	HCC	Homo sapiens	89-92
26134491-9	2015	The epidermal growth factor receptor (EGFR) was confirmed to be a direct target of miR-133a in cervical cancer cells using luciferase assay and western blotting.	mir-133a	83-91	epidermal growth factor receptor	Homo sapiens	4-36
26134491-9	2015	The epidermal growth factor receptor (EGFR) was confirmed to be a direct target of miR-133a in cervical cancer cells using luciferase assay and western blotting.	mir-133a	83-91	epidermal growth factor receptor	Homo sapiens	38-42
26134491-10	2015	Restoration of miR-133a inhibited EGFR expression and activated the AKT and ERK signaling pathways.	mir-133a	15-23	epidermal growth factor receptor	Homo sapiens	34-38
26134491-10	2015	Restoration of miR-133a inhibited EGFR expression and activated the AKT and ERK signaling pathways.	mir-133a	15-23	AKT serine/threonine kinase 1	Homo sapiens	68-71
26134491-11	2015	These results showed that miR-133a suppresses cervical cancer growth in vitro and in vivo through targeting EGFR, suggesting that miR-133a can be a potential target for the treatment of cervical cancer.	mir-133a	26-34	epidermal growth factor receptor	Homo sapiens	108-112
26134491-11	2015	These results showed that miR-133a suppresses cervical cancer growth in vitro and in vivo through targeting EGFR, suggesting that miR-133a can be a potential target for the treatment of cervical cancer.	mir-133a	130-138	epidermal growth factor receptor	Homo sapiens	108-112
25763715-9	2015	H2S mitigates hypertrophy by inducing miR-133a through activation of MEF2C in HHcy cardiomyocytes.	mir-133a	38-46	myocyte enhancer factor 2C	Homo sapiens	69-74
26107945-0	2015	MiR-133a Is Functionally Involved in Doxorubicin-Resistance in Breast Cancer Cells MCF-7 via Its Regulation of the Expression of Uncoupling Protein 2.	mir-133a	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	37-59
26107945-0	2015	MiR-133a Is Functionally Involved in Doxorubicin-Resistance in Breast Cancer Cells MCF-7 via Its Regulation of the Expression of Uncoupling Protein 2.	mir-133a	0-8	uncoupling protein 2	Homo sapiens	129-149
26396670-0	2015	MiR-133a suppresses the migration and invasion of esophageal cancer cells by targeting the EMT regulator SOX4.	mir-133a	0-8	IL2 inducible T cell kinase	Homo sapiens	91-94
26396670-0	2015	MiR-133a suppresses the migration and invasion of esophageal cancer cells by targeting the EMT regulator SOX4.	mir-133a	0-8	SRY-box transcription factor 4	Homo sapiens	105-109
26396670-7	2015	Notably, the EMT marker E-cadherin or vimentin, a downstream of Sox4, was also down-regulated or upregulated upon miR-133a treatment.	mir-133a	114-122	IL2 inducible T cell kinase	Homo sapiens	13-16
26396670-7	2015	Notably, the EMT marker E-cadherin or vimentin, a downstream of Sox4, was also down-regulated or upregulated upon miR-133a treatment.	mir-133a	114-122	cadherin 1	Homo sapiens	24-34
26396670-7	2015	Notably, the EMT marker E-cadherin or vimentin, a downstream of Sox4, was also down-regulated or upregulated upon miR-133a treatment.	mir-133a	114-122	vimentin	Homo sapiens	38-46
26396670-7	2015	Notably, the EMT marker E-cadherin or vimentin, a downstream of Sox4, was also down-regulated or upregulated upon miR-133a treatment.	mir-133a	114-122	SRY-box transcription factor 4	Homo sapiens	64-68
26396670-10	2015	These results demonstrate that miR-133a acts as a tumor suppressor in ESCC through targeting Sox4 and the EMT process.	mir-133a	31-39	SRY-box transcription factor 4	Homo sapiens	93-97
26396670-10	2015	These results demonstrate that miR-133a acts as a tumor suppressor in ESCC through targeting Sox4 and the EMT process.	mir-133a	31-39	IL2 inducible T cell kinase	Homo sapiens	106-109
25815687-6	2015	Furthermore, overexpression of miR-133a inhibited proliferation and invasion, but promoted apoptosis of gastric cancer cells, which may be reversed by upregulation of FSCN1.	mir-133a	31-39	fascin actin-bundling protein 1	Homo sapiens	167-172
25815687-8	2015	In conclusion, the anti-oncogenic activity of miR-133a may involve the inhibition of the target gene FSCN1.	mir-133a	46-54	fascin actin-bundling protein 1	Homo sapiens	101-106
26064437-8	2015	Our results demonstrate that attenuation of miR-133a in diabetic hearts is associated with the induction of autophagy and hypertrophy, and suppression of mTOR without appreciable difference in AMPK activity.	mir-133a	44-52	mechanistic target of rapamycin kinase	Homo sapiens	154-158
25607810-5	2015	To the best of our knowledge, the present study also provided the first evidence that miR-133a directly downregulated the expression of matrix metallopeptidase 9 (MMP-9) in the HCC cells.	mir-133a	86-94	matrix metallopeptidase 9	Homo sapiens	136-161
25607810-5	2015	To the best of our knowledge, the present study also provided the first evidence that miR-133a directly downregulated the expression of matrix metallopeptidase 9 (MMP-9) in the HCC cells.	mir-133a	86-94	matrix metallopeptidase 9	Homo sapiens	163-168
25607810-6	2015	In conclusion, the results of the present study indicated that miR-133a may have suppressed cell proliferation, colony formation, migration and invasion via the downregulation of MMP-9 in HCC cell lines.	mir-133a	63-71	matrix metallopeptidase 9	Homo sapiens	179-184
25780292-0	2015	Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R.	mir-133a	25-33	insulin like growth factor 1 receptor	Homo sapiens	66-71
25780292-7	2015	The regulation of IGF1R by miR-133a was verified using the luciferase reporter assay.	mir-133a	27-35	insulin like growth factor 1 receptor	Homo sapiens	18-23
25780292-9	2015	Downregulation of miR-133a was significantly correlated with the degree of differentiation (P = 0.01), local invasion (P = 0.001) and TNM stage (P = 0.02) in GC patients.	mir-133a	18-26	teneurin transmembrane protein 1	Homo sapiens	134-137
25780292-13	2015	In addition, we identified IGF1R as a regulatory target of miR-133a in GC.	mir-133a	59-67	insulin like growth factor 1 receptor	Homo sapiens	27-32
25780292-14	2015	CONCLUSION: This study suggests that miR-133a is downregulated in GC and functions as a tumor suppressor in vitro and in vivo partly by repressing IGF1R.	mir-133a	37-45	insulin like growth factor 1 receptor	Homo sapiens	147-152
25445891-12	2015	The upregulation of miR-133a in the HASMCs decreased the RhoA expression at the protein level.	mir-133a	20-28	ras homolog family member A	Homo sapiens	57-61
25621061-4	2015	Additionally, restoration of miR-133a expression and downregulation of FSCN1 protein expression suppressed colorectal cancer cell invasion, while overexpression of FSCN1 reversed the inhibitory effect of miR-133a upregulation on colorectal cancer cell invasion.	mir-133a	204-212	fascin actin-bundling protein 1	Homo sapiens	164-169
25621061-5	2015	Thus, the present data indicates that miR-133a may at least partially suppress colorectal cancer cell invasion, possibly via the inhibition of FSCN1 expression.	mir-133a	38-46	fascin actin-bundling protein 1	Homo sapiens	143-148
25317675-6	2015	Using bioinformatics, we identified one putative miR-133a binding site within the 3"-untranslated region of the mouse Foxl2 mRNA.	mir-133a	49-57	forkhead box L2	Mus musculus	118-123
25445891-13	2015	Inversely, the downregulation of miR-133a increased the RhoA protein expression.	mir-133a	33-41	ras homolog family member A	Homo sapiens	56-60
25445891-14	2015	Of note, the overexpression of RhoA in the HASMCs attenuated the anti-proliferative and anti-migratory effects of miR-133a.	mir-133a	114-122	ras homolog family member A	Homo sapiens	31-35
25445891-15	2015	CONCLUSIONS: Our data indicate that miR-133a regulates the functions of HASMCs by targeting RhoA and may be involved in the pathogenesis of ASO.	mir-133a	36-44	ras homolog family member A	Homo sapiens	92-96
25512392-5	2014	Moreover, TEAD1 overexpression antagonized the effect of miR-133a as well as TH on muscle fiber type switch.	mir-133a	57-65	TEA domain transcription factor 1	Homo sapiens	10-15
24816813-6	2014	MiR-133a can inhibit cell invasiveness and cell growth through suppressing the expressions of IGF-1R, TGFBR1 and EGFR, which then influences the downstream signaling in lung cancer cell lines.	mir-133a	0-8	insulin like growth factor 1 receptor	Homo sapiens	94-100
25620172-8	2014	Overexpression of miR-133a inhibits cell growth and invasion and induces cell apoptosis and cycle arrest through repressing TAGLN2 gene, suggesting that miR-133a might be used as a biomarker or therapeutic target for the treatment of gastric cancer.	mir-133a	18-26	transgelin 2	Homo sapiens	124-130
25620172-8	2014	Overexpression of miR-133a inhibits cell growth and invasion and induces cell apoptosis and cycle arrest through repressing TAGLN2 gene, suggesting that miR-133a might be used as a biomarker or therapeutic target for the treatment of gastric cancer.	mir-133a	153-161	transgelin 2	Homo sapiens	124-130
24816813-6	2014	MiR-133a can inhibit cell invasiveness and cell growth through suppressing the expressions of IGF-1R, TGFBR1 and EGFR, which then influences the downstream signaling in lung cancer cell lines.	mir-133a	0-8	transforming growth factor beta receptor 1	Homo sapiens	102-108
24816813-6	2014	MiR-133a can inhibit cell invasiveness and cell growth through suppressing the expressions of IGF-1R, TGFBR1 and EGFR, which then influences the downstream signaling in lung cancer cell lines.	mir-133a	0-8	epidermal growth factor receptor	Homo sapiens	113-117
23968734-0	2013	miR-133a represses tumour growth and metastasis in colorectal cancer by targeting LIM and SH3 protein 1 and inhibiting the MAPK pathway.	mir-133a	0-8	LIM and SH3 protein 1	Homo sapiens	82-103
24513286-6	2014	In parallel, reversine decreases the expression and recruitment of myogenic factor, SRF, to the enhancer regions of miR-133a.	mir-133a	116-124	serum response factor	Mus musculus	84-87
24513286-8	2014	Furthermore, inhibition of miR-133a by transfection of C2C12 myoblasts with miR-133a inhibitor increases the expression of osteogenic lineage marker, Ogn, and adipotenic lineage marker, ApoE, similar to that in response to reversine.	mir-133a	27-35	osteoglycin	Mus musculus	150-153
24513286-8	2014	Furthermore, inhibition of miR-133a by transfection of C2C12 myoblasts with miR-133a inhibitor increases the expression of osteogenic lineage marker, Ogn, and adipotenic lineage marker, ApoE, similar to that in response to reversine.	mir-133a	27-35	apolipoprotein E	Mus musculus	186-190
24513286-8	2014	Furthermore, inhibition of miR-133a by transfection of C2C12 myoblasts with miR-133a inhibitor increases the expression of osteogenic lineage marker, Ogn, and adipotenic lineage marker, ApoE, similar to that in response to reversine.	mir-133a	76-84	osteoglycin	Mus musculus	150-153
24513286-8	2014	Furthermore, inhibition of miR-133a by transfection of C2C12 myoblasts with miR-133a inhibitor increases the expression of osteogenic lineage marker, Ogn, and adipotenic lineage marker, ApoE, similar to that in response to reversine.	mir-133a	76-84	apolipoprotein E	Mus musculus	186-190
24127040-0	2014	miR-133a suppresses ovarian cancer cell proliferation by directly targeting insulin-like growth factor 1 receptor.	mir-133a	0-8	insulin-like growth factor I receptor	Mus musculus	76-113
24127040-5	2014	Through in silico search, we found that the 3"-untranslated region (UTR) of insulin-like growth factor 1 receptor (IGF1R) contains an evolutionarily conserved miR-133a binding site.	mir-133a	159-167	insulin-like growth factor I receptor	Mus musculus	76-113
24127040-5	2014	Through in silico search, we found that the 3"-untranslated region (UTR) of insulin-like growth factor 1 receptor (IGF1R) contains an evolutionarily conserved miR-133a binding site.	mir-133a	159-167	insulin-like growth factor I receptor	Mus musculus	115-120
24127040-8	2014	Taken together, these findings indicate that miR-133a is an important regulator in ovarian cancer, and that its suppressive effects are mediated by targeting IGF1R.	mir-133a	45-53	insulin-like growth factor I receptor	Mus musculus	158-163
24196787-7	2014	Transfection of a miR-133a mimic decreased the mRNA and protein levels of both FSCN1 and MMP14 in ESCC cells.	mir-133a	18-26	fascin actin-bundling protein 1	Homo sapiens	79-84
24196787-7	2014	Transfection of a miR-133a mimic decreased the mRNA and protein levels of both FSCN1 and MMP14 in ESCC cells.	mir-133a	18-26	matrix metallopeptidase 14	Homo sapiens	89-94
25104873-6	2014	The unfavorable prognosis of higher miR-133a expression was accompanied by dysregulation of potential miR-133a target genes, LIM and SH3 domain protein 1 (LASP1), Caveolin-1 (CAV1), and Fascin-1 (FSCN1).	mir-133a	36-44	LIM and SH3 protein 1	Homo sapiens	125-153
25104873-6	2014	The unfavorable prognosis of higher miR-133a expression was accompanied by dysregulation of potential miR-133a target genes, LIM and SH3 domain protein 1 (LASP1), Caveolin-1 (CAV1), and Fascin-1 (FSCN1).	mir-133a	36-44	LIM and SH3 protein 1	Homo sapiens	155-160
25104873-6	2014	The unfavorable prognosis of higher miR-133a expression was accompanied by dysregulation of potential miR-133a target genes, LIM and SH3 domain protein 1 (LASP1), Caveolin-1 (CAV1), and Fascin-1 (FSCN1).	mir-133a	36-44	caveolin 1	Homo sapiens	163-173
25104873-6	2014	The unfavorable prognosis of higher miR-133a expression was accompanied by dysregulation of potential miR-133a target genes, LIM and SH3 domain protein 1 (LASP1), Caveolin-1 (CAV1), and Fascin-1 (FSCN1).	mir-133a	36-44	caveolin 1	Homo sapiens	175-179
25104873-6	2014	The unfavorable prognosis of higher miR-133a expression was accompanied by dysregulation of potential miR-133a target genes, LIM and SH3 domain protein 1 (LASP1), Caveolin-1 (CAV1), and Fascin-1 (FSCN1).	mir-133a	36-44	fascin actin-bundling protein 1	Homo sapiens	186-194
25104873-6	2014	The unfavorable prognosis of higher miR-133a expression was accompanied by dysregulation of potential miR-133a target genes, LIM and SH3 domain protein 1 (LASP1), Caveolin-1 (CAV1), and Fascin-1 (FSCN1).	mir-133a	36-44	fascin actin-bundling protein 1	Homo sapiens	196-201
26629938-6	2014	Overexpression of miR-133a increased the G1 phase of cell cycle and decreased Akt1 expression in BGC-823 cells.	mir-133a	18-26	AKT serine/threonine kinase 1	Homo sapiens	78-82
24506564-6	2014	B-type natriuretic peptide (BNP) moderately correlated with the transcoronary gradients of miR-133a and miR-423-5p.	mir-133a	91-99	natriuretic peptide B	Homo sapiens	0-26
24506564-6	2014	B-type natriuretic peptide (BNP) moderately correlated with the transcoronary gradients of miR-133a and miR-423-5p.	mir-133a	91-99	natriuretic peptide B	Homo sapiens	28-31
24401233-2	2014	This study tested whether miR-133a affects expression of IGF-1 receptor (IGF-1R) and proliferation of IGF-1-stimulated vascular smooth muscle cells (VSMC) in a murine model of atherosclerosis.	mir-133a	26-34	insulin-like growth factor I receptor	Mus musculus	57-71
24401233-2	2014	This study tested whether miR-133a affects expression of IGF-1 receptor (IGF-1R) and proliferation of IGF-1-stimulated vascular smooth muscle cells (VSMC) in a murine model of atherosclerosis.	mir-133a	26-34	insulin-like growth factor I receptor	Mus musculus	73-79
24401233-2	2014	This study tested whether miR-133a affects expression of IGF-1 receptor (IGF-1R) and proliferation of IGF-1-stimulated vascular smooth muscle cells (VSMC) in a murine model of atherosclerosis.	mir-133a	26-34	insulin-like growth factor 1	Mus musculus	57-62
24401233-4	2014	Compared to those in WT aortas, the IGF-1R and miR-133a levels were lower in ApoE(-/-) aortas.	mir-133a	47-55	apolipoprotein E	Mus musculus	77-81
24401233-6	2014	MiR-133a-specific inhibitor decreased miR-133a, IGF-1R expression, IGF-1-stimulated VSMC growth in lipoprotein deficient media.	mir-133a	0-8	insulin-like growth factor I receptor	Mus musculus	48-54
24401233-6	2014	MiR-133a-specific inhibitor decreased miR-133a, IGF-1R expression, IGF-1-stimulated VSMC growth in lipoprotein deficient media.	mir-133a	0-8	insulin-like growth factor 1	Mus musculus	48-53
24401233-13	2014	Administration of miR-133a precursor may potentiate IGF-1-stimulated VSMC survival and growth.	mir-133a	18-26	insulin-like growth factor 1	Mus musculus	52-57
23968734-0	2013	miR-133a represses tumour growth and metastasis in colorectal cancer by targeting LIM and SH3 protein 1 and inhibiting the MAPK pathway.	mir-133a	0-8	mitogen-activated protein kinase 1	Homo sapiens	123-127
23968734-7	2013	In contrast to the phenotypes induced by miR-133a restoration, LASP1-induced cell proliferation and migration rescued miR-133a-mediated biological behaviours, as did LASP1 overexpression.	mir-133a	118-126	LIM and SH3 protein 1	Homo sapiens	63-68
23968734-8	2013	Investigations of possible mechanisms underlying these behaviours revealed that miR-133a modulates the expression of key cellular molecules and participates in the MAPK pathway by inhibiting phosphorylation of ERK and MEK.	mir-133a	80-88	mitogen-activated protein kinase 1	Homo sapiens	164-168
23968734-8	2013	Investigations of possible mechanisms underlying these behaviours revealed that miR-133a modulates the expression of key cellular molecules and participates in the MAPK pathway by inhibiting phosphorylation of ERK and MEK.	mir-133a	80-88	mitogen-activated protein kinase 1	Homo sapiens	210-213
23968734-8	2013	Investigations of possible mechanisms underlying these behaviours revealed that miR-133a modulates the expression of key cellular molecules and participates in the MAPK pathway by inhibiting phosphorylation of ERK and MEK.	mir-133a	80-88	mitogen-activated protein kinase kinase 7	Homo sapiens	218-221
23206218-6	2013	The first evidence was provided that miR-133a and miR-133b may directly target the epidermal growth factor receptor in bladder cancer.	mir-133a	37-45	epidermal growth factor receptor	Homo sapiens	83-115
23798596-6	2013	Overexpression of miR-133a inhibited VSMC transdifferentiation into osteoblast-like cells as evidenced by a decrease in alkaline phosphatase activity, osteocalcin secretion, Runx2 expression, and mineralized nodule formation.	mir-133a	18-26	bone gamma-carboxyglutamate protein	Homo sapiens	151-162
24053180-6	2013	The results showed that circulating miR-133a level was significantly increased in AMI patients in time-dependent manner, and achieved a 72.1 fold peak at 21.6 +- 4.5 hours after the onset of AMI symptoms and exhibited a similar trend to plasma cTnI level.	mir-133a	36-44	troponin I3, cardiac type	Homo sapiens	244-248
23798596-6	2013	Overexpression of miR-133a inhibited VSMC transdifferentiation into osteoblast-like cells as evidenced by a decrease in alkaline phosphatase activity, osteocalcin secretion, Runx2 expression, and mineralized nodule formation.	mir-133a	18-26	RUNX family transcription factor 2	Homo sapiens	174-179
23798596-7	2013	Conversely, the knockdown of miR-133a using an miR-133a inhibitor promoted osteogenic differentiation of VSMCs by increasing alkaline phosphatase activity, osteocalcin secretion, and Runx2 expression.	mir-133a	29-37	bone gamma-carboxyglutamate protein	Homo sapiens	156-167
23798596-7	2013	Conversely, the knockdown of miR-133a using an miR-133a inhibitor promoted osteogenic differentiation of VSMCs by increasing alkaline phosphatase activity, osteocalcin secretion, and Runx2 expression.	mir-133a	29-37	RUNX family transcription factor 2	Homo sapiens	183-188
23798596-8	2013	Runx2 was identified as a direct target of miR-133a by a cotransfection experiment in VSMCs with luciferase reporter plasmids containing wild-type or mutant 3"-untranslated region sequences of Runx2.	mir-133a	43-51	RUNX family transcription factor 2	Homo sapiens	0-5
23798596-8	2013	Runx2 was identified as a direct target of miR-133a by a cotransfection experiment in VSMCs with luciferase reporter plasmids containing wild-type or mutant 3"-untranslated region sequences of Runx2.	mir-133a	43-51	RUNX family transcription factor 2	Homo sapiens	193-198
23798596-9	2013	Furthermore, the pro-osteogenic effects of miR-133a inhibitor were abrogated in Runx2-knockdown cells, and the inhibition of osteogenic differentiation by pre-miR-133a was reversed by overexpression of Runx2, providing functional evidence that the effects of miR-133a in osteogenic differentiation were mediated by targeting Runx2.	mir-133a	43-51	RUNX family transcription factor 2	Homo sapiens	80-85
23798596-9	2013	Furthermore, the pro-osteogenic effects of miR-133a inhibitor were abrogated in Runx2-knockdown cells, and the inhibition of osteogenic differentiation by pre-miR-133a was reversed by overexpression of Runx2, providing functional evidence that the effects of miR-133a in osteogenic differentiation were mediated by targeting Runx2.	mir-133a	43-51	RUNX family transcription factor 2	Homo sapiens	202-207
23798596-9	2013	Furthermore, the pro-osteogenic effects of miR-133a inhibitor were abrogated in Runx2-knockdown cells, and the inhibition of osteogenic differentiation by pre-miR-133a was reversed by overexpression of Runx2, providing functional evidence that the effects of miR-133a in osteogenic differentiation were mediated by targeting Runx2.	mir-133a	43-51	RUNX family transcription factor 2	Homo sapiens	202-207
23798596-9	2013	Furthermore, the pro-osteogenic effects of miR-133a inhibitor were abrogated in Runx2-knockdown cells, and the inhibition of osteogenic differentiation by pre-miR-133a was reversed by overexpression of Runx2, providing functional evidence that the effects of miR-133a in osteogenic differentiation were mediated by targeting Runx2.	mir-133a	159-167	RUNX family transcription factor 2	Homo sapiens	202-207
23798596-9	2013	Furthermore, the pro-osteogenic effects of miR-133a inhibitor were abrogated in Runx2-knockdown cells, and the inhibition of osteogenic differentiation by pre-miR-133a was reversed by overexpression of Runx2, providing functional evidence that the effects of miR-133a in osteogenic differentiation were mediated by targeting Runx2.	mir-133a	159-167	RUNX family transcription factor 2	Homo sapiens	202-207
23786162-6	2013	A dual luciferase reporter gene assay showed that miR-133a bound to the 3" UTR of EGFR but not a mutated 3" UTR, thereby down-regulating the protein expression level.	mir-133a	50-58	epidermal growth factor receptor	Homo sapiens	82-86
23723074-4	2013	Cell-cycle analysis revealed that miR-133a induced a G0/G1-phase arrest, concomitant with the upregulation of the key G1-phase regulator p21(Cip1).	mir-133a	34-42	H3 histone pseudogene 16	Homo sapiens	137-140
23723074-4	2013	Cell-cycle analysis revealed that miR-133a induced a G0/G1-phase arrest, concomitant with the upregulation of the key G1-phase regulator p21(Cip1).	mir-133a	34-42	cyclin dependent kinase inhibitor 1A	Homo sapiens	141-145
23723074-5	2013	We further revealed that miR-133a markedly increased p53 protein and induced p21(Cip1) transcription.	mir-133a	25-33	tumor protein p53	Homo sapiens	53-56
23723074-5	2013	We further revealed that miR-133a markedly increased p53 protein and induced p21(Cip1) transcription.	mir-133a	25-33	H3 histone pseudogene 16	Homo sapiens	77-80
23723074-5	2013	We further revealed that miR-133a markedly increased p53 protein and induced p21(Cip1) transcription.	mir-133a	25-33	cyclin dependent kinase inhibitor 1A	Homo sapiens	81-85
23783274-0	2013	miR-133a suppresses cell proliferation, migration and invasion in human lung cancer by targeting MMP-14.	mir-133a	0-8	matrix metallopeptidase 14	Homo sapiens	97-103
23783274-11	2013	Collectively, these results suggest that miR-133a may inhibit lung cancer metastasis by targeting MMP-14 and may be used as an anti-metastatic therapy in lung cancer patients.	mir-133a	41-49	matrix metallopeptidase 14	Homo sapiens	98-104
23874225-2	2013	Here we show that miR-133a, a microRNA that is expressed in both BAT and SATs, directly targets the 3" UTR of Prdm16.	mir-133a	18-26	PR domain containing 16	Mus musculus	110-116
23069713-6	2013	We also discovered that luciferase activity is exclusively decreased by targeting EGFR in hMSCs transfected with miR-133a mimic.	mir-133a	113-121	epidermal growth factor receptor	Homo sapiens	82-86
25198665-0	2013	miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer.	mir-133a	0-8	fascin actin-bundling protein 1	Homo sapiens	62-67
23874225-3	2013	The expression of miR-133a dramatically decreases along the commitment and differentiation of brown preadipocytes, accompanied by the upregulation of Prdm16.	mir-133a	18-26	PR domain containing 16	Mus musculus	150-156
23874225-4	2013	Overexpression of miR-133a in BAT and SAT cells significantly inhibits, and conversely inhibition of miR-133a upregulates, Prdm16 and brown adipogenesis.	mir-133a	18-26	PR domain containing 16	Mus musculus	123-129
23874225-6	2013	Even 75% deletion of miR-133a (a1(-/-)a2(+/-) ) genes results in browning of SAT, manifested by the appearance of numerous multilocular UCP1-expressing adipocytes within SAT.	mir-133a	21-29	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	136-140
21396852-0	2013	MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines.	mir-133a	0-8	glutathione S-transferase pi 1	Homo sapiens	56-61
21396852-9	2013	MiR-133a transfection repressed expression levels of mRNA and protein levels of GSTP1.	mir-133a	0-8	glutathione S-transferase pi 1	Homo sapiens	80-85
21396852-13	2013	CONCLUSION: Our data suggest that tumor suppressive miR-133a directly regulated oncogenic GSTP1 gene in BC, and that an anti-apoptotic effect mediated by GSTP1 is maintained by miR-133a down-regulation in human BC.	mir-133a	52-60	glutathione S-transferase pi 1	Homo sapiens	90-95
22877943-0	2012	Evidence that miR-133a causes recurrent spontaneous abortion by reducing HLA-G expression.	mir-133a	14-22	major histocompatibility complex, class I, G	Homo sapiens	73-78
22877943-3	2012	This study investigated the role of miR-133a in regulating HLA-G expression and the pathogenesis of recurrent spontaneous abortion (RSA).	mir-133a	36-44	major histocompatibility complex, class I, G	Homo sapiens	59-64
22877943-9	2012	Overexpression of miR-133a in JEG-3 cells decreased HLA-G expression at the protein level, with no effect on mRNA.	mir-133a	18-26	major histocompatibility complex, class I, G	Homo sapiens	52-57
22877943-10	2012	These findings provide strong evidence that miR-133a regulates HLA-G expression by reducing translation and is involved in the pathogenesis of RSA.	mir-133a	44-52	major histocompatibility complex, class I, G	Homo sapiens	63-68